Extracellular matrix 6: Role of matrix metalloproteinase metastasis

FASEB Journal

7, 1434-1441

DOI: 10.1096/fasebj.7.15.8262328

Citation Report

#	Article	IF	Citations
1	Folding and stability of the active N-terminal domain of tissue inhibitor of metalloproteinases-1 and -2. Protein Engineering, Design and Selection, 1994, 7, 1035-1040.	1.0	16
2	Characterization of Bovine Ovarian Surface Epithelium and Stromal Cells: Identification of Secreted Proteins1. Biology of Reproduction, 1994, 51, 1213-1221.	1.2	39
3	The Extracellular Matrix in Cellular Proliferation and Differentiation. Annals of the New York Academy of Sciences, 1994, 733, 87-102.	1.8	39
4	The Family of Matrix Metalloproteinases. Annals of the New York Academy of Sciences, 1994, 732, 11-21.	1.8	415
5	TIMP-1 protein expression is stimulated by IL-1Î² and IL-6 in primary rat hepatocytes. FEBS Letters, 1994, 349, 45-49.	1.3	48
6	Regulation of Proteolytic Activity in Tissues. Critical Reviews in Biochemistry and Molecular Biology, 1994, 29, 315-383.	2.3	96
7	cDNA Sequence and mRNA Tissue Distribution of a Novel Human Matrix Metalloproteinase with a Potential Transmembrane Segment. FEBS Journal, 1995, 231, 602-608.	0.2	87
8	Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms. Cancer, 1995, 75, 1010-1017.	2.0	96
9	Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer and Metastasis Reviews, 1995, 14, 279-301.	2.7	251
10	Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clinical and Experimental Metastasis, 1995, 13, 296-302.	1.7	82
11	Inhibition of collagenase type I expression by psoralen antisense oligonucleotides in dermal fibroblasts. FASEB Journal, 1995, 9, 1371-1377.	0.2	19
12	Gelatinase A activity directly modulates melanoma cell adhesion and spreading.. EMBO Journal, 1995, 14, 908-917.	3.5	154
13	Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB Journal, 1995, 9, 974-980.	0.2	256
14	Identification of a stimulator of steroid hormone synthesis isolated from testis. Science, 1995, 268, 1609-1612.	6.0	141
15	Review. Biological Chemistry Hoppe-Seyler, 1995, 376, 327-356.	1.4	70
16	Steps Involved in Activation of the Pro-matrix Metalloproteinase 9 (Progelatinase B)-Tissue Inhibitor of Metalloproteinases-1 Complex by 4-Aminophenylmercuric Acetate and Proteinases. Journal of Biological Chemistry, 1995, 270, 18506-18511.	1.6	173
17	Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase. Journal of Biological Chemistry, 1995, 270, 5331-5338.	1.6	1,392
18	Autolytic Activation of Recombinant Human 72 Kilodalton Type IV Collagenase. Biochemistry, 1995, 34, 2819-2825.	1.2	77

#	Article	IF	Citations
19	Identification of a component of the sea urchin hyaline layer, HLC-175, which undergoes proteolytic processing during development. International Journal of Biochemistry and Cell Biology, 1995, 27, 675-681.	1.2	1
20	Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain. Gene, 1995, 155, 293-298.	1.0	87
21	The extracellular matrix produced by bovine corneal endothelial cells contains progelatinase A. FEBS Letters, 1995, 361, 61-64.	1.3	15
22	Integrins and reproduction. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1995, 59, 71-81.	0.5	14
23	Urokinaseâ€Type Plasminogen Activator (uPA) and Its Receptor (CD87): A New Target in Tumor Invasion and Metastasis. Journal of Obstetrics and Gynaecology (Tokyo, Japan), 1995, 21, 151-165.	0.1	51
24	Reconstructed 19 kDa Catalytic Domain of Gelatinase A Is an Active Proteinase. Biochemistry, 1995, 34, 4702-4708.	1.2	49
25	A Porcine Model of Chronic Peripheral Arterial Occlusion. Journal of Vascular and Interventional Radiology, 1996, 7, 65-74.	0.2	4
26	Wound fluids and the pathogenesis of chronic wounds*1. Journal of Wound, Ostomy and Continence Nursing, 1996, 23, 283-290.	0.6	25
27	Trophoblast migration during human placental implantation. Human Reproduction Update, 1996, 2, 307-321.	5.2	158
28	Roles of the Propeptide and Metal Ions in the Folding and Stability of the Catalytic Domain of Stromelysin (Matrix Metalloproteinase 3)â€. Biochemistry, 1996, 35, 6549-6558.	1.2	59
29	Metal and pH Dependence of Heptapeptide Catalysis by Human Matrilysinâ€. Biochemistry, 1996, 35, 15831-15838.	1.2	45
30	Extracellular matrix-remodeling metalloproteinases and infection of the central nervous system with retrovirus human T-lymphotropic virus type I (HTLV-I). Progress in Neurobiology, 1996, 49, 169-184.	2.8	44
31	High plasma level of plasmin-Î±2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Clinica Chimica Acta, 1996, 244, 69-81.	0.5	21
32	The Helping Hand of Collagenase-3 (MMP-13): 2.7 Ã… Crystal Structure of its C-terminal Haemopexin-like Domain. Journal of Molecular Biology, 1996, 264, 556-566.	2.0	139
33	Expression of metalloproteinases and tissue inhibitors of metalloproteinases in giant cell tumor of bone: An immunohistochemical study with clinical correlation. Human Pathology, 1996, 27, 1144-1148.	1.1	24
34	Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelialization. Atherosclerosis, 1996, 126, 95-104.	0.4	14
35	Differentiation arrest by autologously replicating DNA loops formed along differentiation pathway: An hypothesis of carcinogenesis. Medical Hypotheses, 1996, 47, 129-135.	0.8	0
36	Regulation of Vascular Smooth Muscle Cell Migration and Proliferation In Vitro and in Injured Rat Arteries by a Synthetic Matrix Metalloproteinase Inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 28-33.	1.1	282

#	Article	IF	Citations
37	Cooperation between Matrix Metalloproteinases and the Plasminogen Activator-Plasmin System in Tumor Progression. Enzyme & Protein, 1996, 49, 72-84.	1.6	84
38	The role of matrix metalloproteinases in heart disease. Cardiovascular Research, 1996, 32, 816-821.	1.8	62
39	Expression of Matrix-Metalloproteinases and their Inhibitors in Human Cholesteatomas. Acta Oto-Laryngologica, 1996, 116, 451-456.	0.3	52
41	Syndecan-1 alterations during the tumorigenic progression of human colonic Caco-2 cells induced by human Ha-ras or polyoma middle T oncogenes. British Journal of Cancer, 1996, 74, 423-431.	2.9	21
42	Shedding of Human Thyrotropin Receptor Ectodomain. Journal of Biological Chemistry, 1996, 271, 4545-4552.	1.6	131
43	Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analyses. Biochemical Journal, 1996, 313, 827-833.	1.7	14
44	Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases. Clinical and Experimental Metastasis, 1996, 15, 26-32.	1.7	44
45	Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Seminars in Cancer Biology, 1996, 7, 147-154.	4.3	325
46	Computational sequence analysis of matrix metalloproteinases. The Protein Journal, 1996, 15, 137-160.	1.1	106
47	Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochirurgica, 1996, 138, 1442-1448.	0.9	39
48	Three-dimensional analysis of the substrate-dependent invasive behavior of a human lung tumor cell line with a confocal laser scanning microscope. Histochemistry and Cell Biology, 1996, 105, 179-185.	0.8	10
49	Regulation of Membrane-Type Matrix Metalloproteinase-1 Expression by Growth Factors and Phorbol 12-Myristate 13-Acetate. FEBS Journal, 1996, 239, 239-247.	0.2	167
50	Serum markers for fibrosis and plasma transforming growth factor-Î²1in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 443-450.	1.4	18
51	Chromosome 14 alteration is associated with increased collagenase expression and the metastatic potential of murine melanomas. Cancer Genetics and Cytogenetics, 1996, 92, 66-72.	1.0	3
52	Serum Markers for Hepatic Fibrosis in Alcoholic Liver Disease: Which Is the Best Marker, Type III Procollagen, Type IV Collagen, Laminin, Tissue Inhibitor of Metalloproteinase, or Prolyl Hydroxylase?. Alcoholism: Clinical and Experimental Research, 1996, 20, 1512-1517.	1.4	31
53	Matrix metal loproteinases and the development of cancer. Chemistry and Biology, 1996, 3, 895-904.	6.2	498
54	Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. , 1996, 67, 423-429.		80
55	Matrilysin expression in human prostate carcinoma. , 1996, 15, 57-63.		74

#	Article	IF	Citations
56	DISRUPTION OF CELLâ€“CELL ADHESION IN THE PRESENCE OF SODIUM BUTYRATE ACTIVATES EXPRESSION OF THE 92kDa TYPE IV COLLAGENASE IN MDCK CELLS. Cell Biology International, 1996, 20, 489-499.	1.4	9
57	Mechanisms of tumor invasion and metastasis. World Journal of Urology, 1996, 14, 124-30.	1.2	36
58	Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Investigational New Drugs, 1996, 14, 193-202.	1.2	105
59	The Epithelial to Mesenchymal Transition and Metastatic Progression in Carcinoma. Breast Journal, 1996, 2, 83-96.	0.4	76
60	The Proteolytic Potential of Normal Human Melanocytes: Comparison With Other Skin Cells and Melanoma Cell Lines. Pigment Cell & Melanoma Research, 1996, 9, 255-264.	4.0	8
61	Tumor protease-activated, pore-forming toxins from a combinatorial library. Nature Biotechnology, 1996, 14, 852-856.	9.4	67
62	Differential Expression of Tissue Inhibitor of Metalloproteinases-2 by Cutaneous Squamous and Basal Cell Carcinomas. Journal of Investigative Dermatology, 1996, 106, 321-326.	0.3	21
63	Evidence of the Involvement of Phosphatidylinositol 3-Kinase in the Migration, Actin Stress Fiber Formation, and Î±vÎ²3-Integrinâ€“Mediated Adherence of Human Melanoma Cells. Journal of Investigative Dermatology, 1996, 107, 597-602.	0.3	21
64	Matrix metalloproteinase-7 expression in gastric carcinoma.. Gut, 1996, 39, 444-448.	6.1	90
65	Matrix metalloproteinaseâ€“1 is associated with poor prognosis in colorectal cancer. Nature Medicine, 1996, 2, 461-462.	15.2	404
66	Structure and Domain-Domain Interactions of the Gelatin-binding Site of Human 72-Kilodalton Type IV Collagenase (Gelatinase A, Matrix Metalloproteinase 2). Journal of Biological Chemistry, 1996, 271, 12003-12008.	1.6	44
67	Purification and metal ion requirements of a candidate matrix metalloproteinase: a 41â€‚kDa gelatinase activity in the sea urchin embryo. Biochemistry and Cell Biology, 1996, 74, 211-218.	0.9	23
68	Messenger ribonucleic acid levels of collagenase (MMP-13) and matrilysin (MMP-7) in virgin, pregnant, and postpartum uterus and cervix of rat.. Endocrinology, 1996, 137, 5429-5434.	1.4	30
69	Integrins and Other Cell Adhesion Molecules in Endometrium and Endometriosis. Seminars in Reproductive Medicine, 1997, 15, 291-299.	0.5	49
70	Expression of matrix metalloproteinases 1 and 2 genes in a possible association with metastatic abilities of human pancreatic cancer cells. International Journal of Oncology, 1997, 10, 623-628.	1.4	6
71	The Matrix Metalloproteinase-14 (MMP-14) Gene Is Structurally Distinct from Other MMP Genes and Is Co-expressed with the TIMP-2 Gene during Mouse Embryogenesis. Journal of Biological Chemistry, 1997, 272, 25511-25517.	1.6	130
72	Mechanisms of Glioma Invasion: Role of Matrix-Metalloproteinases. Canadian Journal of Neurological Sciences, 1997, 24, 3-15.	0.3	114
73	Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - a predictor of tumour stage. British Journal of Cancer, 1997, 76, 805-811.	2.9	84

#	Article	IF	Citations
74	A Gene Delivery System Activatable by Disease-Associated Matrix Metalloproteinases. Human Gene Therapy, 1997, 8, 729-738.	1.4	94
75	Site-Directed Mutagenesis of the Active Site Glutamate in Human Matrilysin:Â Investigation of Its Role in Catalysisâ€. Biochemistry, 1997, 36, 16019-16024.	1.2	74
76	Increased Focal Adhesion Kinase- and Urokinase-Type Plasminogen Activator Receptor-Associated Cell Signaling in Endothelial Cells Exposed to Asbestos. Environmental Health Perspectives, 1997, 105, 1131.	2.8	2
77	Effect of adenosine analogues on the expression of matrix metalloproteinases and their inhibitors from human dermal fibroblasts. Biochemical Pharmacology, 1997, 53, 1511-1520.	2.0	11
78	Activation of Gelatinase A (72-kDa Type IV Collagenase) Induced by Monensin in Normal Human Fibroblasts. Experimental Cell Research, 1997, 232, 322-330.	1.2	25
79	Assignment of the Human Genes for Membrane-Type-1, -2, and -3 Matrix Metalloproteinases (MMP14,) Tj ETQq1 1 0.784314 rgBT /Over 1997, 39, 412-413.	1.3	22
80	Structural and functional aspects of calcium binding in extracellular matrix proteins. Matrix Biology, 1997, 15, 569-580.	1.5	70
81	Expression of tissue inhibitor of metalloproteinase-1 and type IV collagenase/gelatinase messenger RNAs in human breast cancer. Human Pathology, 1997, 28, 359-366.	1.1	20
82	Murine tissue inhibitor of metalloproteinases-4 (Timp -4): cDNA isolation and expression in adult mouse tissues 1. FEBS Letters, 1997, 401, 213-217.	1.3	167
83	Structural features and biochemical properties of TNF-Î± converting enzyme (TACE). Journal of Neuroimmunology, 1997, 72, 127-129.	1.1	106
84	Cloning, expression and activation of a truncated 92-kDa gelatinase minienzyme. Gene, 1997, 196, 175-180.	1.0	13
85	Increased focal adhesion kinase- and urokinase-type plasminogen activator receptor-associated cell signaling in endothelial cells exposed to asbestos.. Environmental Health Perspectives, 1997, 105, 1131-1137.	2.8	13
86	Thrombin Receptor-Mediated Increase of Two Matrix Metalloproteinases, MMP-1 and MMP-3, in Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1931-1938.	1.1	90
87	Postsurgical wound progression monitored by temporal changes in the expression of matrix metalloproteinase-9. British Journal of Dermatology, 1997, 137, 506-516.	1.4	72
88	Immunolocalization of interstitial collagenase (MMP-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1)in radicular cysts. Journal of Oral Pathology and Medicine, 1997, 26, 458-463.	1.4	40
89	Human Collagenase-3 Is Expressed in Malignant Squamous Epithelium of the Skin. Journal of Investigative Dermatology, 1997, 109, 225-231.	0.3	150
90	In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene, 1997, 14, 1351-1359.	2.6	98
91	Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. British Journal of Pharmacology, 1997, 121, 540-546.	2.7	121

#	Article	IF	Citations
92	Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nature Medicine, 1997, 3, 171-176.	15.2	205
93	1.8-A Crystal Structure of the Catalytic Domain of Human Neutrophil Collagenase (Matrix) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Distinct Selectivity Profile. FEBS Journal, 1997, 247, 356-363.	0.2	69
94	The nitric oxide donor S-nitroso-N-acetyl-D,L-penicillamine degrades heparan sulfate and heparin. IUBMB Life, 1997, 43, 183-188.	1.5	1
95	Computational sequence analysis of the tissue inhibitor of metalloproteinase family. The Protein Journal, 1997, 16, 237-255.	1.1	91
96	Matrix metalloproteinase inhibitors. Investigational New Drugs, 1997, 15, 61-75.	1.2	400
97	Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. Clinical and Experimental Metastasis, 1997, 16, 74-82.	1.7	32
98	Elevated cyclic AMP suppresses ConA-induced MT1-MMP expression in MDA-MB-231 human breast cancer cells. Clinical and Experimental Metastasis, 1997, 16, 185-191.	1.7	24
99	Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clinical and Experimental Metastasis, 1997, 15, 440-446.	1.7	70
100	Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clinical and Experimental Metastasis, 1997, 15, 499-508.	1.7	77
101	Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries. Molecular Diversity, 1997, 2, 135-146.	2.1	30
102	Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. Bioorganic and Medicinal Chemistry, 1997, 5, 2193-2201.	1.4	41
103	Matrix metalloproteinases and tissue inhibitors of metalloproteinases in thyroid Câ€cells and medullary thyroid carcinomas. Histopathology, 1997, 31, 150-156.	1.6	23
104	Antifibroproliferative effect of tenidap in chronic antigen-induced arthritis. Arthritis and Rheumatism, 1997, 40, 2147-2156.	6.7	8
105	Osteoarthritis: Differential expression of matrix metalloproteinase-9 mRNA in nonfibrillated and fibrillated cartilage. Journal of Orthopaedic Research, 1997, 15, 94-100.	1.2	28
106	Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo. , 1997, 32, 196-204.		45
107	Characterization of a metalloproteinase: A late stage specific gelatinase activity in the sea urchin embryo. Journal of Cellular Biochemistry, 1997, 66, 337-345.	1.2	19
108	Quantitative Reverse Zymography: Analysis of Picogram Amounts of Metalloproteinase Inhibitors Using Gelatinase A and B Reverse Zymograms. Analytical Biochemistry, 1997, 244, 161-166.	1.1	160
109	Stimulation of cellular growth and adhesion to fibronectin and vitronectin in culture and tumorigenicity in nude mice by overexpression of trypsinogen in human gastric cancer cells. Clinical and Experimental Metastasis, 1998, 16, 613-621.	1.7	41

#	Article	IF	Citations
110	Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clinical and Experimental Metastasis, 1998, 16, 217-225.	1.7	129
111	Expression and Activity of Urokinase and Its Receptor in Endothelial and Pulmonary Epithelial Cells Exposed to Asbestos. Toxicology and Applied Pharmacology, 1998, 152, 388-396.	1.3	29
112	Diuretic response to cyclophosphamide in rats bearing a matrix metalloproteinase-9-producing tumour. British Journal of Cancer, 1998, 78, 1030-1034.	2.9	4
113	A zinc chelator inhibiting gelatinases exerts potent in vitro anti-invasive effects. European Journal of Pharmacology, 1998, 351, 225-233.	1.7	13
114	Loss of epithelial differentiation markers and acquisition of vimentin expression after xenograft with laminin-1 enhance migratory and invasive abilities of human colon cancer cells LoVo C5. Differentiation, 1998, 63, 141-150.	1.0	12
115	Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. , 1998, 82, 642-650.		132
116	Over-expression of urokinase receptor in human epidermoid-carcinoma cell line (HEp3) increases tumorigenicity on chorio-allantoic membrane and in severe-combined-immunodeficient mice. , 1998, 77, 257-263.		15
117	Verapamil inhibits tumor protease production, local invasion and metastasis development in murine carcinoma cells. , 1998, 78, 727-734.		24
118	Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. , 1998, 185, 256-261.		244
119	Aberrant type I and type III collagen gene expression in human breast cancerin vivo. , 1998, 186, 262-268.		216
120	Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. , 1998, 35, 248-254.		22
121	Calciumâ€“protein interactions in the extracellular environment: Calcium binding, activation, and immunolocalization of a collagenase/gelatinase activity expressed in the sea urchin embryo. , 1998, 71, 546-558.		12
122	Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)-mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. , 1998, 176, 255-265.		190
123	Molecular pattern of ductal pancreatic cancer. Langenbecks Archiv Fur Chirurgie, 1998, 383, 105.	0.2	43
124	Matrix metalloproteinases MMPâ€2 and MMPâ€9 in denervated muscle and injured nerve. Neuropathology and Applied Neurobiology, 1998, 24, 309-319.	1.8	79
125	Protein tyrosine phosphorylation in signalling pathways leading to the activation of gelatinase A: activation of gelatinase A by treatment with the protein tyrosine phosphatase inhibitor sodium orthovanadate. Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1405, 110-120.	1.9	20
126	Oligosaccharides of recombinant mouse gelatinase B variants. Biochimica Et Biophysica Acta - General Subjects, 1998, 1425, 587-598.	1.1	24
127	Dipeptidyl peptidase III in malignant and non-malignant gynaecological tissue. European Journal of Cancer, 1998, 34, 399-405.	1.3	40

#	Article	IF	Citations
128	Matrix metalloproteinase digestion of aggrecan in human cartilage tumours. European Journal of Cancer, 1998, 34, 1969-1973.	1.3	8
129	Myocardial Extracellular Matrix Remodeling with the Development of Pacing Induced Congestive Heart Failure. Cardiovascular Pathology, 1998, 7, 161-168.	0.7	3
130	MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: Possible implications for the role of desmoplastic fibroblasts. Human Pathology, 1998, 29, 155-165.	1.1	86
131	Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity. Cell, 1998, 92, 391-400.	13.5	589
132	Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Letters, 1998, 424, 262-266.	1.3	88
133	Expression of membrane-type matrix metalloproteinase-1 in human pancreatic adenocarcinomas. Journal of Cancer Research and Clinical Oncology, 1998, 124, 65-72.	1.2	36
134	Physiology and healing dynamics of chronic cutaneous wounds. American Journal of Surgery, 1998, 176, 26S-38S.	0.9	717
135	Solution Structure of the Catalytic Domain of Human Stromelysin-1 Complexed to a Potent, Nonpeptidic Inhibitor. Biochemistry, 1998, 37, 14048-14056.	1.2	41
136	Presence of an N-Terminal Polyhistidine Tag Facilitates Stable Expression of an Otherwise Unstable N-Terminal Domain of Mouse Tissue Inhibitor of Metalloproteinase-1 inEscherichia coli. Protein Expression and Purification, 1998, 13, 67-72.	0.6	10
137	Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 Ã... resolution. Journal of Molecular Biology, 1998, 284, 1133-1140.	2.0	91
138	Short Chain Fatty Acids Inhibit Human (SW1116) Colon Cancer Cell Invasion by Reducing Urokinase Plasminogen Activator Activity and Stimulating TIMP-1 and TIMP-2 Activities, Rather Than via MMP Modulation. Journal of Surgical Research, 1998, 76, 41-46.	0.8	50
139	Novel Therapeutic Strategies to Selectively Kill Cancer Cells. Biochemical Pharmacology, 1998, 55, 247-252.	2.0	82
141	Matrix metalloproteinases and their inhibitors in gastric cancer. Gut, 1998, 43, 791-797.	6.1	152
142	TIMP-2 Promotes Activation of Progelatinase A by Membrane-type 1 Matrix Metalloproteinase Immobilized on Agarose Beads. Journal of Biological Chemistry, 1998, 273, 16098-16103.	1.6	234
143	Heterogeneity Among Cells That Express Osteoclast-Associated Genes in Developing Bone. Endocrinology, 1998, 139, 340-349.	1.4	29
144	Production of Membrane-type Matrix Metalloproteinase-1 (MT-MMP-1) in Early Human Placenta: A Possible Role in Placental Implantation?. Journal of Histochemistry and Cytochemistry, 1998, 46, 221-229.	1.3	51
145	Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA.. International Journal of Oncology, 1998, 13, 1285-90.	1.4	6
146	Application of Chemically Modified Tetracyclines (CMTs) in Experimental Models of Cancer and Arthritis. Advances in Dental Research, 1998, 12, 103-110.	3.6	10

#	Article	IF	Citations
147	Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.. Journal of Clinical Oncology, 1998, 16, 2150-2156.	0.8	233
148	Ontogeny of Extracellular Matrix Gene Expression by Rat Lung Cells at Late Fetal Gestation. Neonatology, 1998, 73, 112-120.	0.9	18
149	Matrix Metalloproteinases and Their Inhibitors in Human Pituitary Tumors. Neurosurgery, 1999, 45, 1432-1441.	0.6	45
150	Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H777-H787.	1.5	64
151	Expression of Trypsin in Human Cancer Cell Lines and Cancer Tissues and Its Tight Binding to Soluble Form of Alzheimer Amyloid Precursor Protein in Culture. Journal of Biochemistry, 1999, 125, 1067-1076.	0.9	65
152	Models for Studying Cellular Invasion of Basement Membranes. , 1999, 129, 231-250.		8
153	92K-GL (MMP-9) and 72K-GL (MMP-2) are Produced in vivo by Human Oral Squamous Cell Carcinomas and can Enhance FIB-CL (MMP-1) Activity in vitro. Journal of Dental Research, 1999, 78, 1354-1361.	2.5	8
154	Expression Pattern of the Plasminogen Activatorâ€"Plasmin System in Human Cholesteatoma. Annals of Otology, Rhinology and Laryngology, 1999, 108, 245-252.	0.6	5
155	A Novel Host/Tumor Cell Interaction Activates Matrix Metalloproteinase 1 and Mediates Invasion through Type I Collagen. Journal of Biological Chemistry, 1999, 274, 25371-25378.	1.6	91
156	Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts. Journal of Biological Chemistry, 1999, 274, 36505-36512.	1.6	468
158	Mechanism(s) of attenuation of Theileria annulata vaccine cell lines. Tropical Medicine and International Health, 1999, 4, A78-A84.	1.0	42
159	The extracellular matrix in skin tumor development â€" a morphological study. Journal of Cutaneous Pathology, 1999, 26, 327-338.	0.7	24
160	MMP-9 Activity in Urine from Patients with Various Tumors, as Measured by a Novel MMP Activity Assay Using Modified Urokinase as a Substrate. Annals of the New York Academy of Sciences, 1999, 878, 141-149.	1.8	20
161	The Matrix Metalloproteinases and Their Inhibitors in the Treatment of Pancreatic Cancer. Annals of the New York Academy of Sciences, 1999, 880, 288-307.	1.8	86
162	A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. British Journal of Haematology, 1999, 105, 303-312.	1.2	11
163	Increased E1AF expression in mouse fibrosarcoma promotes metastasis through induction of MT1-MMP expression. Oncogene, 1999, 18, 1771-1776.	2.6	51
164	Transcriptional repression of the human collagenase-1 (MMP-1) gene in MDA231 breast cancer cells by all-trans-retinoic acid requires distal regions of the promoter. British Journal of Cancer, 1999, 79, 221-228.	2.9	29
165	Role of zinc and Î±2macroglobulin on thymic endocrine activity and on peripheral immune efficiency (natural killer activity and interleukin 2) in cervical carcinoma. British Journal of Cancer, 1999, 79, 244-250.	2.9	34

#	Article	IF	Citations
166	Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. British Journal of Cancer, 1999, 80, 495-503.	2.9	131
167	â€˜Proteolytic switchingâ€™: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. British Journal of Cancer, 1999, 80, 504-512.	2.9	59
168	Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. British Journal of Cancer, 1999, 80, 733-743.	2.9	206
169	Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo. British Journal of Cancer, 1999, 81, 654-661.	2.9	38
170	MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Research and Treatment, 1999, 58, 285-291.	1.1	42
171	Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src. Clinical and Experimental Metastasis, 1999, 17, 105-110.	1.7	24
172	Alterations in proteolytic activity at low pH and its association with invasion: a theoretical model. Clinical and Experimental Metastasis, 1999, 17, 397-407.	1.7	52
173	High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clinical and Experimental Metastasis, 1999, 17, 799-808.	1.7	162
174	Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clinical and Experimental Metastasis, 1999, 17, 555-566.	1.7	121
175	Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Clinical and Experimental Metastasis, 1999, 17, 1-18.	1.7	41
176	Gelatinase A and Membrane-type 1 Matrix Metalloproteinase mRNA: Expressed in Adrenocortical Cancers but Not in Adenomas. World Journal of Surgery, 1999, 23, 237-242.	0.8	22
177	Matrix metalloproteinases and tissue inhibitors of metalloproteinases in some endocrine organs and their tumors. Endocrine Pathology, 1999, 10, 15-26.	5.2	8
178	Secretion of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 by Meningiomas Detected by Cell Immunoblot Analysis. Acta Neurochirurgica, 1999, 141, 481-486.	0.9	21
179	Influenza A virus infection modulates the expression of type IV collagenase in epithelial cells. Archives of Virology, 1999, 144, 1361-1370.	0.9	30
180	Inhibition of contact sensitizer-induced migration of human Langerhans cells by matrix metalloproteinase inhibitors. Archives of Dermatological Research, 1999, 291, 447-452.	1.1	24
181	Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma. Journal of Cancer Research and Clinical Oncology, 1999, 125, 541-548.	1.2	39
182	Matrix metalloproteinases and oral cancer. Oral Oncology, 1999, 35, 227-233.	0.8	138
183	The gelatin-binding site of the second type-II domain of gelatinase Ã¯Â¿Â½A/MMP-2. FEBS Journal, 1999, 259, 513-518.	0.2	35

#	Article	IF	Citations
184	Increased TIMP-1 activity results in increased expression of gelatinases and altered cell motility. , 1999, 75, 346-355.		19
185	Tissue inhibitor of metalloproteinase-2 (TIMP-2) expression is strongly induced by ACTH in adrenocortical cells. , 1999, 180, 372-380.		3
186	Laminin receptor ?6?4 integrin is highly expressed in ENU-induced glioma in rat. Glia, 1999, 26, 55-63.	2.5	7
187	Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. , 1999, 86, 1929-1935.		28
188	Matrix metalloproteinase-2 (MMP-2) immunoreactive protein?a new prognostic marker in uveal melanoma?. , 1999, 188, 56-62.		64
190	Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Canadian Journal of Physiology and Pharmacology, 1999, 77, 465-480.	0.7	130
191	Secretion of 92kDa gelatinase (MMP-9) by bovine neutrophils. Veterinary Immunology and Immunopathology, 1999, 67, 247-258.	0.5	39
192	Metal loproteases in remodeling of vascular extracellular matrix. Fibrinolysis and Proteolysis, 1999, 13, 54-63.	1.1	20
194	Identification and cloning of a novel isoform of mouse secretory leukocyte protease inhibitor, mSLPI-Î², overexpressed in murine leukemias and a highly liver metastatic tumor, IMC-HA1 cells. Advances in Enzyme Regulation, 1999, 39, 341-355.	2.9	10
195	Affinity and Selectivity of Matrix Metalloproteinase Inhibitors:Â A Chemometrical Study from the Perspective of Ligands and Proteinsâ€. Journal of Medicinal Chemistry, 1999, 42, 4506-4523.	2.9	68
196	Structure of recombinant mouse collagenase-3 (MMP-13). Journal of Molecular Biology, 1999, 292, 837-844.	2.0	44
197	Interstitial Pathomechanisms Underlying Progressive Tubulointerstitial Damage. Kidney and Blood Pressure Research, 1999, 22, 71-80.	0.9	46
198	Proteolysis in colorectal cancer. Journal of Clinical Pathology, 1999, 52, 140-145.	2.1	28
199	The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells. Molecular and Cellular Biology, 1999, 19, 5902-5912.	1.1	194
200	Cinnamamide, an antitumor agent with low cytotoxicity acting on matrix metalloproteinase. Anti-Cancer Drugs, 2000, 11, 49-54.	0.7	14
201	Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. Journal of Pathology, 2000, 191, 245-256.	2.1	159
202	Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer, 2000, 89, 995-1003.	2.0	35
203	Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer, 2000, 89, 1329-1348.	2.0	48

#	Article	IF	Citations
204	Metalloproteinase expression in normal and malignant oral keratinocytes: stimulation of MMP-2 and -9 by scatter factor. European Journal of Oral Sciences, 2000, 108, 281-291.	0.7	35
205	A Single Nucleotide Polymorphism in the Matrix Metalloproteinase-1 Promoter in Endometrial Carcinomas. Japanese Journal of Cancer Research, 2000, 91, 612-615.	1.7	81
206	Effect of a matrix metalloproteinase inhibitor on host resistance againstListeria monocytogenesinfection. FEMS Immunology and Medical Microbiology, 2000, 29, 187-194.	2.7	9
207	Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Digestive Diseases and Sciences, 2000, 45, 114-121.	1.1	45
208	Antioxidants inhibit TNFalpha-induced motility and invasion of human osteosarcoma cells: possible involvement of NFkappaB activation. Clinical and Experimental Metastasis, 2000, 18, 121-129.	1.7	20
209	Zinc, metallothioneins, immune responses, survival and ageing. Biogerontology, 2000, 1, 133-143.	2.0	94
210	TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clinical and Experimental Metastasis, 2000, 18, 493-499.	1.7	48
211	Matrix metalloproteinases in tumor invasion and metastasis. Seminars in Cancer Biology, 2000, 10, 415-433.	4.3	656
212	Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer. British Journal of Cancer, 2000, 82, 960-965.	2.9	42
213	Enhanced migration of the acute promyelocytic leukemia cell line NB4 under in vitro conditions during short-term all-trans-retinoic acid treatment. Journal of Cancer Research and Clinical Oncology, 2000, 126, 33-40.	1.2	32
214	Mechanisms of tumor metastasis: cell biological aspects and clinical implications. Journal of Cancer Research and Clinical Oncology, 2000, 126, 682-692.	1.2	111
215	Cathepsin A activity in primary and metastatic human melanocytic tumors. Archives of Dermatological Research, 2000, 292, 68-71.	1.1	34
216	Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-Î± and leaves RANTES and MCP-2 intact. Blood, 2000, 96, 2673-2681.	0.6	615
217	Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies. Journal of Clinical Oncology, 2000, 18, 178-178.	0.8	76
218	Trypsin Stimulates Integrin Î±5Î²1-dependent Adhesion to Fibronectin and Proliferation of Human Gastric Carcinoma Cells through Activation of Proteinase-activated Receptor-2. Journal of Biological Chemistry, 2000, 275, 4592-4598.	1.6	103
219	Membrane-type matrix metalloproteinase-9 activity in placental tissue from patients with pre-existing and gestational diabetes mellitus. Reproduction, Fertility and Development, 2000, 12, 269.	0.1	39
220	Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-Î± Convertase Activity but Does Not Activate Pro-MMP2. Journal of Biological Chemistry, 2000, 275, 14046-14055.	1.6	195
221	Localization of Urokinase Type Plasminogen Activator to Focal Adhesions Requires Ligation of Vitronectin Integrin Receptors. Cell Adhesion and Communication, 2000, 7, 477-490.	1.7	16

#	Article	IF	Citations
222	Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. British Journal of Cancer, 2000, 83, 215-218.	2.9	50
223	Serum Matrix Metalloproteinase-2 as a Prognostic Marker in Advanced Cutaneous Melanoma. Acta OncolÃ³gica, 2000, 39, 877-879.	0.8	17
224	Matrix Metalloproteinases-2, -3, -7, -9 and -10, But Not MMP-11, Are Differentially Expressed in Normal, Benign Tumorigenic and Malignant Human Keratinocyte Cell Lines. Biological Chemistry, 2000, 381, 497-507.	1.2	39
225	High Levels of Matrix Metalloproteinases Regulate Proliferation and Hormone Secretion in Pituitary Cells1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 263-269.	1.8	66
226	Role of Matrix Metalloproteinase 9 in Pituitary Tumor Behavior. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2931-2935.	1.8	93
227	Wild Type and Mutant p53 Differentially Regulate the Gene Expression of Human Collagenase-3 (hMMP-13). Journal of Biological Chemistry, 2000, 275, 11327-11332.	1.6	83
228	Matrix Metalloproteinase and Î±vÎ²3 Integrinâ€“Dependent Vascular Smooth Muscle Cell Invasion Through a Type I Collagen Lattice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 998-1005.	1.1	80
229	Chronic AT ₁ Blockade Stimulates Extracellular Collagen Type I Degradation and Reverses Myocardial Fibrosis in Spontaneously Hypertensive Rats. Hypertension, 2000, 35, 1197-1202.	1.3	134
230	Type IV Collagen Induces Matrix Metalloproteinase 2 Activation in HT1080 Fibrosarcoma Cells. Experimental Cell Research, 2000, 261, 348-359.	1.2	64
231	Macrophages Secrete Matrix Metalloproteinase 9 Covalently Linked to the Core Protein of Chondroitin Sulphate Proteoglycans. Journal of Molecular Biology, 2000, 304, 669-680.	2.0	79
232	The effect of gallium nitrate on synoviocyte MMP activity. Biochimie, 2000, 82, 147-151.	1.3	17
233	Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Molecular and Cellular Endocrinology, 2000, 167, 99-106.	1.6	27
234	Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer. Cancer Letters, 2000, 151, 81-86.	3.2	29
235	Differential Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Protein and mRNA in Epithelial Ovarian Tumors. Gynecologic Oncology, 2000, 77, 369-376.	0.6	49
236	Solitary Lung Tumors and Their Spontaneous Metastasis in Athymic Nude Mice Orthotopically Implanted with Human Non-Small Cell Lung Cancer. Neoplasia, 2000, 2, 315-324.	2.3	26
237	A Metalloproteinase Inhibitor Prevents Acute Graft-Versus-Host Disease While Preserving the Graft-Versus-Leukaemia Effect of Allogeneic Bone Marrow Transplantation. Leukemia and Lymphoma, 2000, 38, 553-561.	0.6	11
238	Identification and characterization of gelatin-cleavage activities in the apically located extracellular matrix of the sea urchin embryo. Biochemistry and Cell Biology, 2000, 78, 455-462.	0.9	10
239	Tail Vein Assay of Cancer Metastasis. Current Protocols in Cell Biology, 2001, 12, 19.2.1-19.2.7.	2.3	64

#	Article	IF	Citations
240	Calreticulin Is Directly Involved in Anti-Î±3 Integrin Antibody-Mediated Secretion and Activation of Matrix Metalloprotease-2. Biochemical and Biophysical Research Communications, 2001, 283, 297-302.	1.0	19
241	Expression of matrix metalloproteinases and the metastasis-associated gene S100A4 in human neuroblastoma and primitive neuroectodermal tumor cells. Journal of Pediatric Surgery, 2001, 36, 1040-1044.	0.8	15
242	Gelatinase B: a tuner and amplifier of immune functions. Trends in Immunology, 2001, 22, 571-579.	2.9	363
243	Potential methods to prevent interstitial fibrosis in renal disease. Expert Opinion on Investigational Drugs, 2001, 10, 1989-2001.	1.9	18
244	Matrix Metalloproteinases-2 and 9 Do Not Play a Role in the Growth of Preneoplastic Liver Lesions in F344 Rats. Experimental Biology and Medicine, 2001, 226, 799-803.	1.1	6
245	Expression of Gelatinase-A (MMP-2) in Human Colon Cancer and Normal Colon Mucosa. Tumor Biology, 2001, 22, 383-389.	0.8	46
246	The role of the tubular epithelial cell in renal fibrogenesis. Clinical and Experimental Nephrology, 2001, 5, 62-74.	0.7	3
247	Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clinical and Experimental Immunology, 2001, 125, 340-344.	1.1	66
248	Matrix metalloproteinases and their inhibitors in oral lichen planus. Journal of Cutaneous Pathology, 2001, 28, 72-82.	0.7	89
249	Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma. Cancer, 2001, 91, 1739-1744.	2.0	26
250	Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma. Cancer, 2001, 92, 2680-2691.	2.0	75
251	Granulocyte colony-stimulating factor (G-CSF)-mediated signaling regulates type IV collagenase activity in head and neck cancer cells. International Journal of Cancer, 2001, 93, 42-46.	2.3	25
252	Expression of CD44v3 splice variant is associated with the visceral metastatic phenotype of human melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 439, 628-635.	1.4	27
253	Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Therapy, 2001, 8, 869-878.	2.2	69
254	Chemokine-Induced Secretion of Gelatinase B in Primary Human Monocytes. Biological Chemistry, 2001, 382, 1405-10.	1.2	45
255	Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. British Journal of Cancer, 2001, 84, 1664-1670.	2.9	51
256	Osteopontin Stimulates Tumor Growth and Activation of Promatrix Metalloproteinase-2 through Nuclear Factor-Î¹B-mediated Induction of Membrane Type 1 Matrix Metalloproteinase in Murine Melanoma Cells. Journal of Biological Chemistry, 2001, 276, 44926-44935.	1.6	225
257	Rac1 Mediates Type I Collagen-dependent MMP-2 Activation. Journal of Biological Chemistry, 2001, 276, 16248-16256.	1.6	154

#	Article	IF	Citations
258	Collagen Matrix in Development and Progression of Experimentally Induced Respiratory Neoplasms in the Hamster. Toxicologic Pathology, 2001, 29, 514-527.	0.9	9
260	Metalloproteinase 2 activity and modulation in uterus from neonatal streptozotocin-induced diabetic rats during embryo implantation. Reproduction, Fertility and Development, 2002, 14, 479.	0.1	12
261	Hepatocarcinoma cell lines down-regulate matrix metalloproteinase-2 expression in human hepatic myofibroblasts. International Journal of Oncology, 2002, 20, 1129.	1.4	1
262	Leukocyte Elastase Negatively Regulates Stromal Cell-derived Factor-1 (SDF-1)/CXCR4 Binding and Functions by Amino-terminal Processing of SDF-1 and CXCR4. Journal of Biological Chemistry, 2002, 277, 15677-15689.	1.6	189
263	The Molecular Biology of Pancreatic Cancer. , 2002, , 15-28.		2
264	Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs). Current Gene Therapy, 2002, 2, 255-271.	0.9	54
265	Stimulation of Matrix Metalloproteinase-9 Expression in Human Fibrosarcoma Cells by Synthetic Matrix Metalloproteinase Inhibitors. Experimental Cell Research, 2002, 275, 110-121.	1.2	27
266	Intrabronchial orthotopic propagation of human lung adenocarcinomaâ€"characterizations of tumorigenicity, invasion and metastasis. Lung Cancer, 2002, 36, 271-276.	0.9	28
267	Proteases and Their Inhibitors in Gliomas. , 2002, , 241-268.		2
268	Les mÃ©talloprotÃ©ases matricielles et leurs inhibiteurs synthÃ©tiques dans la progression tumorale. Medecine/Sciences, 2002, 18, 565-575.	0.0	8
269	Dilinoleoylphosphatidylcholine prevents transforming growth factor-Î²1-mediated collagen accumulation in cultured rat hepatic stellate cells. Translational Research, 2002, 139, 202-210.	2.4	46
270	Proteolysis of the Abdominal Aortic Aneurysm Wall and the Association with Rupture. European Journal of Vascular and Endovascular Surgery, 2002, 23, 153-157.	0.8	73
271	Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Cancer Detection and Prevention, 2002, 26, 222-228.	2.1	43
272	Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncology, 2002, 38, 195-200.	0.8	85
273	Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells. International Journal of Cancer, 2002, 97, 157-162.	2.3	70
274	Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer, 2002, 95, 1963-1970.	2.0	84
275	Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. Journal of Cellular Physiology, 2002, 191, 208-216.	2.0	53
276	Infiltration anesthetic lidocaine inhibits cancer cell invasion by modulating ectodomain shedding of heparin-binding epidermal growth factor-like growth factor (HB-EGF). Journal of Cellular Physiology, 2002, 192, 351-358.	2.0	59

#	Article	IF	Citations
277	Physiopathology of cancer metastases in bone and of the changes they induce in bone remodeling. Rendiconti Lincei, 2002, 13, 181-246.	1.0	4
278	New Molecular Targets of Breast Cancer Therapy. Strahlentherapie Und Onkologie, 2002, 178, 123-133.	1.0	23
279	Embryogenesis of the rat heart: the expression of collagenases. Basic Research in Cardiology, 2002, 97, 189-197.	2.5	31
280	Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma. British Journal of Surgery, 2002, 88, 1596-1601.	0.1	21
281	Membrane Type 1 Matrix Metalloproteinase Regulates Cellular Invasiveness and Survival in Cutaneous Epidermal Cells. Journal of Investigative Dermatology, 2002, 118, 573-581.	0.3	18
282	Keratinocyte Survival, Differentiation, and Death: Many Roads Lead to Mitogen-Activated Protein Kinase. Journal of Investigative Dermatology Symposium Proceedings, 2002, 7, 36-40.	0.8	107
283	Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. Journal of Gastroenterology and Hepatology (Australia), 2002, 14, 138-145.	1.4	53
284	Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. Clinical Biochemistry, 2002, 35, 383-388.	0.8	26
285	MT-MMPs play pivotal roles in cancer dissemination. Clinical and Experimental Metastasis, 2002, 19, 209-215.	1.7	74
286	The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clinical and Experimental Metastasis, 2002, 19, 275-282.	1.7	88
287	Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma. Clinical and Experimental Metastasis, 2002, 19, 583-591.	1.7	25
288	Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer and Metastasis Reviews, 2003, 22, 177-203.	2.7	190
289	Role of pericellular proteolysis by membrane-type 1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer and Metastasis Reviews, 2003, 22, 129-143.	2.7	83
290	Clinical implications of matrix metalloproteinases. Molecular and Cellular Biochemistry, 2003, 252, 305-329.	1.4	135
291	The inhibitory effects of an antisense u-PAR vector on invasion of highly invasive human prostate carcinoma PC-3M cell subclones. Journal of Huazhong University of Science and Technology [Medical Sciences], 2003, 23, 101-104.	1.0	0
293	Tumor cytosol dipeptidyl peptidase III activity is increased with histological aggressiveness of ovarian primary carcinomas. Gynecologic Oncology, 2003, 91, 194-200.	0.6	49
294	Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 2003, 98, 119-127.	2.0	243
295	A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. International Journal of Cancer, 2003, 106, 372-374.	2.3	56

#	Article	IF	Citations
296	Multiple myeloma biology: lessons from the 5TMM models. Immunological Reviews, 2003, 194, 196-206.	2.8	113
297	Expression of extracellular matrix markers in benign meningiomas. Neuropathology, 2003, 23, 275-281.	0.7	43
298	An ELISA for the detection of TIMP-1 based on recombinant single chain Fv fusion proteins. Clinica Chimica Acta, 2003, 335, 49-57.	0.5	2
299	Matrix metalloproteinases in a gerbil cholesteatoma model. Otolaryngology - Head and Neck Surgery, 2003, 129, 402-407.	1.1	6
300	Tympanic membrane metalloproteinase inflammatory response. Otolaryngology - Head and Neck Surgery, 2003, 129, 647-654.	1.1	15
301	Identification and partial characterization of two inducible gelatin-cleavage activities localized to the sea urchin extraembryonic matrix, the hyaline layer. Biochimica Et Biophysica Acta - General Subjects, 2003, 1621, 67-75.	1.1	3
302	Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Human Pathology, 2003, 34, 80-88.	1.1	39
303	Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in human oral squamous cell carcinoma and the effect of protein kinase C inhibitors: Preliminary observations. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2003, 95, 710-716.	1.6	43
304	The signal of proteinase-activated receptor-2 plays an important role in pancreatic cancer progression. International Congress Series, 2003, 1255, 333-338.	0.2	0
305	Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax, 2003, 58, 198-203.	2.7	57
306	The Calpastatin-Derived Calpain Inhibitor CP1B Reduces mRNA Expression of Matrix Metalloproteinase-2 and -9 and Invasion by Leukemic THP-1 Cells. Biological Chemistry, 2003, 384, 951-8.	1.2	25
307	3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate inhibits cancer cell invasion in vitro and tumour growth in vivo. British Journal of Cancer, 2003, 88, 1111-1118.	2.9	93
308	Matrix Assembly Induction and Cell Migration and Invasion Inhibition by a 13-Amino Acid Fibronectin Peptide. Journal of Biological Chemistry, 2003, 278, 14346-14355.	1.6	23
309	Molecular techniques on bronchial wash samples could enhance diagnostic pick-up rate in lung cancer. Thorax, 2003, 58, 203-203.	2.7	0
310	Angiogenesis in Endocrine Tumors. Endocrine Reviews, 2003, 24, 600-632.	8.9	251
311	Osteopontin Induces Nuclear Factor Î°B-mediated Promatrix Metalloproteinase-2 Activation through IÎ°BÎ±/IKK Signaling Pathways, and Curcumin (Diferulolylmethane) Down-regulates These Pathways. Journal of Biological Chemistry, 2003, 278, 14487-14497.	1.6	220
312	HGF, MET, and Matrix-Related Proteases in Hepatocellular Carcinoma, Fibrolamellar Variant, Cirrhotic and Normal Liver. Modern Pathology, 2003, 16, 14-21.	2.9	39
313	Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro. American Journal of Physiology - Cell Physiology, 2003, 284, C805-C815.	2.1	67

#	Article	IF	Citations
314	Zinc-Binding Proteins (Metallothionein and Î±-2 Macroglobulin) as Potential Biological Markers of Immunosenescence. NeuroImmune Biology, 2004, , 23-40.	0.2	6
315	Stromal Matrix Metalloproteinase-9 Regulates the Vascular Architecture in Neuroblastoma by Promoting Pericyte Recruitment. Cancer Research, 2004, 64, 1675-1686.	0.4	203
316	Matrix-metalloproteinase Activity in First Trimester Placental Bed Biopsies in Further Complicated and Uncomplicated Pregnancies. Placenta, 2004, 25, 253-258.	0.7	32
317	Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancerâ€"MMP-9 correlates to the grade and the stage. Gynecologic Oncology, 2004, 94, 699-704.	0.6	79
318	Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma.. Journal of Cancer Research and Clinical Oncology, 2004, 130, 37-44.	1.2	98
319	Membrane Type-1 Matrix Metalloproteinase Promotes Human Melanoma Invasion and Growth. Journal of Investigative Dermatology, 2004, 122, 167-176.	0.3	59
320	Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatric Blood and Cancer, 2004, 42, 410-415.	0.8	57
321	Ethanol-inducedin vitro invasion of breast cancer cells: The contribution of MMP-2 by fibroblasts. International Journal of Cancer, 2004, 112, 738-746.	2.3	48
322	Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis. Journal of Gene Medicine, 2004, 6, 1228-1237.	1.4	25
323	Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells. International Journal of Biochemistry and Cell Biology, 2004, 36, 2293-2306.	1.2	36
324	Tumor promoter-induced MMP-13 gene expression in a model of initiated epidermis. Biochemical and Biophysical Research Communications, 2004, 317, 570-577.	1.0	10
326	Application of real-time RT-PCR to quantifying gene expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human abdominal aortic aneurysm. Atherosclerosis, 2004, 177, 353-360.	0.4	37
327	Synthesis and maturation of type I and type III collagens in endometrial adenocarcinoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2004, 115, 66-74.	0.5	19
328	The Influence of Platelets on the Promotion of Invasion by Tumor Cells and Inhibition by Antiplatelet Agents. Pancreas, 2004, 29, 132-140.	0.5	71
329	Effect of a Synthetic Matrix Metalloproteinase Inhibitor (ONO-4817) on Neointima Formation in Hypercholesterolemic Hamsters. Journal of Cardiovascular Pharmacology, 2004, 44, 57-65.	0.8	8
330	Immunotherapy and Cancer Vaccines in the Management of Breast Cancer. Current Pharmaceutical Design, 2005, 11, 3475-3483.	0.9	12
331	Review of: Opposing roles for specific TIMPs in breast cancer prognosis. Breast Cancer Online: BCO, 2005, 8, .	0.1	1
332	Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents. Applied Radiation and Isotopes, 2005, 62, 903-913.	0.7	9

#	Article	IF	Citations
333	Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. International Journal of Experimental Pathology, 2005, 86, 347-363.	0.6	168
334	Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases. Biochemical Pharmacology, 2005, 71, 21-31.	2.0	16
335	Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts. Experimental and Molecular Pathology, 2005, 78, 36-40.	0.9	35
336	Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecologic Oncology, 2005, 99, 656-663.	0.6	52
337	Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: Enhanced susceptibility to nasopharyngeal carcinoma. International Journal of Cancer, 2005, 115, 368-376.	2.3	66
338	Molecular and cellular basis of cancer invasion and metastasis: Implications for treatment. British Journal of Surgery, 2005, 81, 1576-1590.	0.1	114
339	Matrix metalloproteinase 19 processes the laminin 5 gamma 2 chain and induces epithelial cell migration. Cellular and Molecular Life Sciences, 2005, 62, 870-880.	2.4	65
340	Up-regulation of fibronectin in oesophageal squamous cell carcinoma is associated with activation of the Erk pathway. Journal of Pathology, 2005, 207, 402-409.	2.1	34
341	A microarray study to characterize the molecular mechanism of TIMP-3-mediated tumor rejection. Molecular Therapy, 2005, 12, 144-152.	3.7	18
342	Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clinical Chemistry and Laboratory Medicine, 2005, 43, 934-8.	1.4	24
343	Cancer Gene Therapy. Technology in Cancer Research and Treatment, 2005, 4, 315-330.	0.8	32
344	Hydroxamate-based peptide inhibitors of matrix metalloprotease 2. Biochimie, 2005, 87, 385-392.	1.3	40
345	Visualization of Tumor Cell Extravasation. , 2006, 13, 200-208.		12
346	Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: Prognostic value of TIMP-1 in severe sepsis. Scandinavian Journal of Infectious Diseases, 2006, 38, 867-872.	1.5	90
347	Phlorotannins in Ecklonia cava extract inhibit matrix metalloproteinase activity. Life Sciences, 2006, 79, 1436-1443.	2.0	192
348	Tetracyclines: Nonantibiotic properties and their clinical implications. Journal of the American Academy of Dermatology, 2006, 54, 258-265.	0.6	632
349	Signal of proteinase-activated receptor-2 contributes to highly malignant potential of human pancreatic cancer by up-regulation of interleukin-8 release. International Journal of Oncology, 2006, 28, 939.	1.4	7
350	Inflammatory Gene Expression Patterns Revealed by DNA Microarray Analysis in TNF-Î±-treated SGBS Human Adipocytes. Yonsei Medical Journal, 2006, 47, 729.	0.9	27

#	Article	IF	Citations
351	Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncology Reports, 2006, 15, 539.	1.2	45
352	Implication of MT1-MMP in the maturation steps of benign melanocytic nevi. Journal of Cutaneous Pathology, 2006, 33, 139-144.	0.7	4
353	Molecular pathology of odontogenic tumors. Journal of Oral Pathology and Medicine, 2006, 35, 65-74.	1.4	87
354	Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas. Pathology Research and Practice, 2006, 202, 365-372.	1.0	29
355	Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Molecular and Cellular Biochemistry, 2006, 287, 109-116.	1.4	158
356	Zinc-binding proteins (metallothionein and Î±-2 macroglobulin) and immunosenescence. Experimental Gerontology, 2006, 41, 1094-1107.	1.2	74
357	Metalloproteinases and their inhibitors: Influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head and Neck, 2006, 28, 31-39.	0.9	45
358	Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression. Journal of Surgical Oncology, 2006, 93, 330-337.	0.8	70
359	Molecular spectrum of pigmented skin lesions: from nevus to melanoma. Expert Review of Dermatology, 2006, 1, 679-700.	0.3	2
360	Expression of Matrix Metalloproteinase-7 on Cancer Cells and Tissue Endothelial Cells in Renal Cell Carcinoma: Prognostic Implications and Clinical Significance for Invasion and Metastasis. Clinical Cancer Research, 2006, 12, 6998-7003.	3.2	71
361	What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. European Journal of Endocrinology, 2007, 156, 143-153.	1.9	101
362	MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. International Journal of Oncology, 2007, 30, 985-92.	1.4	24
363	Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clinica Chimica Acta, 2007, 379, 31-35.	0.5	24
364	Transcriptional upregulation of human cathepsin L by VEGF in glioblastoma cells. Gene, 2007, 399, 129-136.	1.0	26
365	Modulation of Cholesterol Homeostasis by Antiproliferative Drugs in Human Pterygium Fibroblasts. , 2007, 48, 3450.		23
366	Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nature Cell Biology, 2007, 9, 893-904.	4.6	888
367	A singleâ€nucleotide polymorphism in the matrix metalloproteinaseâ€1 promoter enhances bladder cancer susceptibility. BJU International, 2008, 101, 503-507.	1.3	29
368	Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chemico-Biological Interactions, 2007, 165, 220-229.	1.7	38

#	Article	IF	Citations
369	Usefulness of MMP-9/TIMP-1 in Predicting Tumor Recurrence in Patients Undergoing Curative Surgical Resection for Gastric Carcinoma. Digestive Diseases and Sciences, 2007, 52, 753-759.	1.1	14
370	Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. Endocrine, 2007, 31, 311-320.	2.2	20
371	Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. Cancer Chemotherapy and Pharmacology, 2008, 63, 167-174.	1.1	21
372	The metzincins â€" Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a super family of zincâ€peptidases. Protein Science, 1995, 4, 823-840.	3.1	614
373	Lymphocyte/macrophage interactions: Biomaterial surfaceâ€dependent cytokine, chemokine, and matrix protein production. Journal of Biomedical Materials Research - Part A, 2008, 87A, 676-687.	2.1	85
374	Serum levels of tissue inhibitor of metalloproteinasesâ€2 and of precursor form of matrix metalloproteinaseâ€2 in patients with liver disease. Liver, 1997, 17, 293-299.	0.1	34
375	Value of Fibrosis Markers for Staging Liver Fibrosis in Patients With Precirrhotic Alcoholic Liver Disease. Alcoholism: Clinical and Experimental Research, 2008, 32, 1031-1039.	1.4	59
376	Role of metalloproteinases at the onset of liver development. Development Growth and Differentiation, 2008, 50, 331-338.	0.6	35
377	Melanoma Associated Spongiform Scleropathy: Characterization, Biochemical and Immunohistochemical studies. Acta Ophthalmologica, 2008, 86, 1-25.	0.6	11
378	Aberrant expression of Î²-dystroglycan may be due to processing by matrix metalloproteinases-2 and -9 in oral squamous cell carcinoma. Oral Oncology, 2008, 44, 1139-1146.	0.8	16
379	Prognostic Values of Matrix Metalloproteinase Family Expression in Human Colorectal Carcinoma. Journal of Surgical Research, 2008, 146, 32-42.	0.8	68
380	Matrix Metalloproteinases in Critical Limb Ischemia. Journal of Surgical Research, 2008, 149, 148-154.	0.8	12
381	Altered Gene Expression Levels of Matrix Metalloproteinases and Their Inhibitors in Periodontitisâ€Affected Gingival Tissue. Journal of Periodontology, 2008, 79, 166-173.	1.7	86
382	Modelling Tumour Acidity and Invasion. Novartis Foundation Symposium, 2008, 240, 169-185.	1.2	13
383	VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. Journal of Cell Science, 2009, 122, 4089-4098.	1.2	114
384	Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells. Phytomedicine, 2009, 16, 573-580.	2.3	79
385	Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha. Journal of Bone and Mineral Research, 1995, 10, 1374-1384.	3.1	31
386	Collagen-based cell migration models in vitro and in vivo. Seminars in Cell and Developmental Biology, 2009, 20, 931-941.	2.3	558

#	Article	IF	Citations
387	Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells. Journal of Ethnopharmacology, 2009, 126, 252-257.	2.0	58
388	Up-Regulation of Soluble Axl and Mer Receptor Tyrosine Kinases Negatively Correlates with Gas6 in Established Multiple Sclerosis Lesions. American Journal of Pathology, 2009, 175, 283-293.	1.9	89
389	Clinical Considerations in the Treatment of Acne Vulgaris and Other Inflammatory Skin Disorders: a Status Report. Dermatologic Clinics, 2009, 27, 1-15.	1.0	39
390	Heparin inhibits the production of matrix metalloproteinase-2 and improves atherosclerosis in LDL receptor-deficient mice. Coronary Artery Disease, 2010, 21, 39-45.	0.3	5
391	Gene alterations in head and neck carcinomas and their role in promoting malignant behavior (Review). International Journal of Oncology, 2010, 36, 525-32.	1.4	5
392	Bacoside A downregulates matrix metalloproteinases 2 and 9 in DENâ€induced hepatocellular carcinoma. Cell Biochemistry and Function, 2010, 28, 164-169.	1.4	26
393	Metalloproteinases and their regulators in colorectal cancer. Journal of Surgical Oncology, 2010, 101, 259-269.	0.8	29
394	Regulation of MT1â€MMP activity by Î²â€catenin in MDCK nonâ€cancer and HT1080 cancer cells. Journal of Cellular Physiology, 2010, 225, 810-821.	2.0	22
395	Constituents isolated from Glehnia littoralis suppress proliferations of human cancer cells and MMP expression in HT1080 cells. Food Chemistry, 2010, 120, 385-394.	4.2	26
396	Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. Journal of Biomedical Science, 2010, 17, 10.	2.6	74
397	Bladder Cancer Risk Associated with Genotypic Polymorphism of the Matrix Metalloproteinase-1 and 7 in North Indian Population. Disease Markers, 2010, 29, 37-46.	0.6	34
398	Claudin-4 expression is associated with tumor invasion, MMP-2 and MMP-9 expression in gastric cancer. Experimental and Therapeutic Medicine, 2010, 1, 789-797.	0.8	35
399	Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Are Essential for the Inflammatory Response in Cancer Cells. Journal of Signal Transduction, 2010, 2010, 1-7.	2.0	67
400	Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma. Carcinogenesis, 2010, 31, 1669-1675.	1.3	23
401	MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells. Modern Pathology, 2010, 23, 511-521.	2.9	42
402	Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinomaâ˜†. Human Pathology, 2011, 42, 57-67.	1.1	56
403	Adrenomedullin production is increased in colorectal adenocarcinomas; its relation to matrix metalloproteinase-9. Peptides, 2011, 32, 1825-1831.	1.2	13
404	Matrix metalloproteinases 2 and 9 in the cochlea: expression and activity after aminoglycoside exposition. Neuroscience, 2011, 181, 28-39.	1.1	19

#	Article	IF	Citations
405	Increased alpha-taxilin protein expression is associated with the metastatic and invasive potential of renal cell cancer. Biomedical Research, 2011, 32, 103-110.	0.3	19
406	Physiopathology of Spine Metastasis. International Journal of Surgical Oncology, 2011, 2011, 1-8.	0.3	115
407	Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells. Clinical and Experimental Metastasis, 2011, 28, 463-477.	1.7	46
408	Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma. Journal of Surgical Oncology, 2011, 103, 243-247.	0.8	37
409	Denbinobin, a phenanthrene from dendrobium nobile, inhibits invasion and induces apoptosis in SNU-484 human gastric cancer cells. Oncology Reports, 2012, 27, 813-8.	1.2	41
410	Caffeic Acid Phenethyl Ester Inhibits Oral Cancer Cell Metastasis by Regulating Matrix Metalloproteinase-2 and the Mitogen-Activated Protein Kinase Pathway. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-10.	0.5	37
411	Significance of PELP1 in ER-Negative Breast Cancer Metastasis. Molecular Cancer Research, 2012, 10, 25-33.	1.5	38
412	Classification Framework and Chemical Biology of Tetracycline-Structure-Based Drugs. Antibiotics, 2012, 1, 1-13.	1.5	69
413	Role of Estrogen Receptor Signaling in Breast Cancer Metastasis. International Journal of Breast Cancer, 2012, 2012, 1-8.	0.6	141
414	Markers of Inflammation and Fibrosis in Alcoholic Hepatitis and Viral Hepatitis C. International Journal of Hepatology, 2012, 2012, 1-10.	0.4	52
415	Low dose aspirin prevents duodenoesophageal reflux induced mucosal changes inÂwistar rat esophagus by MAP kinase mediated pathways. International Journal of Surgery, 2012, 10, 73-79.	1.1	4
416	u-PA inhibitor amiloride suppresses peritoneal metastasis in gastric cancer. World Journal of Surgical Oncology, 2012, 10, 270.	0.8	13
417	Molecular Genetics and Biology of Head and Neck Squamous Cell Carcinoma: Implications for Diagnosis, Prognosis and Treatment. , 2012, , .		5
418	Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma. Experimental and Molecular Pathology, 2012, 92, 236-242.	0.9	32
419	MT1-MMP in breast cancer: induction of VEGF-C correlates with metastasis and poor prognosis. Cancer Cell International, 2013, 13, 98.	1.8	25
420	Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer. Breast, 2013, 22, 330-334.	0.9	29
421	Silencing of HEPN1 is Responsible for the Aggressive Biological Behavior of Pituitary Somatotroph Adenomas. Cellular Physiology and Biochemistry, 2013, 31, 379-388.	1.1	10
422	Apicidin-Resistant HA22T Hepatocellular Carcinoma Cells strongly activated the Wnt/Î²-Catenin Signaling Pathway and MMP-2 Expression via the IGF-IR/PI3K/Akt Signaling Pathway Enhancing Cell Metastatic Effect. Bioscience, Biotechnology and Biochemistry, 2013, 77, 2397-2404.	0.6	26

#	Article	IF	Citations
423	The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma. Experimental and Therapeutic Medicine, 2013, 5, 890-896.	0.8	22
424	Meta-Analysis of MMP2, MMP3, and MMP9 Promoter Polymorphisms and Head and Neck Cancer Risk. PLoS ONE, 2013, 8, e62023.	1.1	35
425	The Role of E-Cadherin-Catenin Complex in Prostate Cancer Progression. , 0, , .		0
426	The Effect of Imiquimod on Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Malignant Melanoma Cell Invasion. Annals of Dermatology, 2014, 26, 363.	0.3	10
427	Nanocapsulated quercetin downregulates rat hepatic MMP-13 and controls diethylnitrosamine-induced carcinoma. Nanomedicine, 2014, 9, 2323-2337.	1.7	28
428	Presence of matrix metalloproteinaseâ€“2 and tissue inhibitor matrix metalloproteinaseâ€“2 gene polymorphisms and immunohistochemical expressions in intracranial meningiomas. Journal of Neurosurgery, 2014, 121, 1478-1482.	0.9	10
429	Matrix Metalloproteinases: The Gene Expression Signatures of Head and Neck Cancer Progression. Cancers, 2014, 6, 396-415.	1.7	36
430	Invasive Potential of Melanoma Cells Correlates with the Expression of MT1-MMP and Regulated by Modulating Its Association with Motility Receptors via N-Glycosylation on the Receptors. BioMed Research International, 2014, 2014, 1-10.	0.9	10
431	Effects of mechanical properties on tumor invasion: Insights from a cellular model. , 2014, 2014, 6818-21.		3
432	Barriers to drug delivery in solid tumors. Tissue Barriers, 2014, 2, e29528.	1.6	236
433	The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: a meta-analysis. Tumor Biology, 2014, 35, 3047-3052.	0.8	37
434	Recruitment and retention: factors that affect pericyte migration. Cellular and Molecular Life Sciences, 2014, 71, 299-309.	2.4	64
435	Effect of small interfering RNAs on matrix metalloproteinase 1 expression. Biotechnology Reports (Amsterdam, Netherlands), 2014, 4, 5-13.	2.1	1
436	Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene, 2014, 33, 3707-3716.	2.6	92
437	Nonâ€antibiotic properties of tetracyclines and their clinical application in dermatology. Australasian Journal of Dermatology, 2014, 55, 111-118.	0.4	51
438	Glycosylation of the laminin receptor (Î±3Î²1) regulates its association with tetraspanin CD151: Impact on cell spreading, motility, degradation and invasion of basement membrane by tumor cells. Experimental Cell Research, 2014, 322, 249-264.	1.2	29
439	Claudin-4 expression in gastric cancer cells enhances the invasion and is associated with the increased level of matrix metalloproteinase-2 and -9 expression. Oncology Letters, 2014, 8, 1367-1371.	0.8	37
440	Evaluation of Matrix Metalloproteinases-2 (MMP-2) and Tissue Inhibitors of Metalloproteinases-2 (TIMP-2) in Oral Submucous Fibrosis and Their Correlation With Disease Severity. Kathmandu University Medical Journal, 2015, 11, 274-281.	0.1	7

#	Article	IF	Citations
441	Matrix metalloproteinase variants associated with risk and clinical outcome of esophageal cancer. Genetics and Molecular Research, 2015, 14, 4616-4624.	0.3	15
442	Solution-Phase Crosstalk and Regulatory Interactions Between Multipotent Adult Progenitor Cells and Peripheral Blood Mononuclear Cells. Stem Cells Translational Medicine, 2015, 4, 1436-1449.	1.6	5
443	The analytical performance of a porous silicon Bloch surface wave biosensors as protease biosensor. Sensors and Actuators B: Chemical, 2015, 211, 469-475.	4.0	19
444	Maclurin suppresses migration and invasion of human non-small-cell lung cancer cells via anti-oxidative activity and inhibition of the Src/FAKâ€“ERKâ€“Î²-catenin pathway. Molecular and Cellular Biochemistry, 2015, 402, 243-252.	1.4	29
445	Resveratrol suppresses <scp>TPA</scp>â€induced matrix metalloproteinaseâ€9 expression through the inhibition of <scp>MAPK</scp> pathways in oral cancer cells. Journal of Oral Pathology and Medicine, 2015, 44, 699-706.	1.4	52
446	Matrix Metalloproteinase-1 (MMP1) Polymorphism is Associated with Lowered Risk of Nasopharyngeal Carcinoma in Asian Population. Cell Biochemistry and Biophysics, 2015, 71, 999-1004.	0.9	7
447	Association between matrix metalloproteinase-2 and matrix metalloproteinase-9 polymorphisms and endometriosis: A systematic review and meta-analysis. Biomedical Reports, 2015, 3, 559-565.	0.9	17
448	Practical Medical and Surgical Management of Chronic Rhinosinusitis. , 2015, , .		7
449	Ursolic acid inhibits the invasive phenotype of SNU-484 human gastric cancer cells. Oncology Letters, 2015, 9, 897-902.	0.8	46
450	Caffeic Acid Phenethyl Ester Is a Potential Therapeutic Agent for Oral Cancer. International Journal of Molecular Sciences, 2015, 16, 10748-10766.	1.8	73
452	Zeolite scaffolds for cultures of human breast cancer cells. Part II: Effect of pure and hybrid zeolite membranes on neoplastic and metastatic activity control. Materials Science and Engineering C, 2016, 68, 474-481.	3.8	6
453	Multiâ€spectroscopic and molecular modeling investigation of the interactions between prantschimgin and matrix metalloproteinase 9 (MMP9). Luminescence, 2016, 31, 587-593.	1.5	7
454	Genetic polymorphisms in MMP 2, 3 and 9 genes and the susceptibility of osteosarcoma in a Chinese Han population. Biomarkers, 2016, 21, 160-163.	0.9	9
455	Matrix metalloproteinases as candidate biomarkers in adults with congenital heart disease. Biomarkers, 2016, 21, 466-473.	0.9	11
456	Genetic polymorphisms in MMP 2, 3, 7, and 9 genes and the susceptibility and clinical outcome of cervical cancer in a Chinese Han population. Tumor Biology, 2016, 37, 4883-4888.	0.8	17
457	Inhibitory effects of Leucaena leucocephala on the metastasis and invasion of human oral cancer cells. Environmental Toxicology, 2017, 32, 1765-1774.	2.1	18
458	Evaluation of Suppressive Effects of Tranilast on the Invasion/Metastasis Mechanism in a Murine Pancreatic Cancer Cell Line. Pancreas, 2017, 46, 567-574.	0.5	2
459	Temozolomide does not influence the transcription or activity of matrix metalloproteinases 9 and 2 in glioma cell lines. Journal of Clinical Neuroscience, 2017, 41, 144-149.	0.8	6

#	Article	IF	Citations
460	Tissue and serum mRNA profile of MMPs-2/9 as a potential novel biomarker for the most individual approach in infantile hemangiomas and cancer disease. Immunobiology, 2017, 222, 1035-1042.	0.8	8
461	Clinicopathologic and Prognostic Significance of Gelatinase A in Tunisian Colorectal Cancer: A Case-Control Study. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 64-70.	0.6	1
462	Recent advances in macromolecular prodrugs. Current Opinion in Colloid and Interface Science, 2017, 31, 1-9.	3.4	24
463	Kaempferol Inhibits the Invasion and Migration of Renal Cancer Cells through the Downregulation of AKT and FAK Pathways. International Journal of Medical Sciences, 2017, 14, 984-993.	1.1	82
464	Helix aspersa maxima mucus exhibits antimelanogenic and antitumoral effects against melanoma cells. Biomedicine and Pharmacotherapy, 2018, 101, 871-880.	2.5	31
465	S100A10 upregulation associates with poor prognosis in lung squamous cell carcinoma. Biochemical and Biophysical Research Communications, 2018, 505, 466-470.	1.0	14
466	Potential of the Bioinspired CaCO₃ Microspheres Loaded with Tetracycline in Inducing Differential Cytotoxic Effects toward Noncancerous and Cancer Cells: A Cytogenetic Toxicity Assessment Using CHO Cells in Vitro. Chemical Research in Toxicology, 2018, 31, 629-636.	1.7	12
467	A combination of bovine serum albumin with insulinâ€“transferrinâ€“sodium selenite and/or epidermal growth factor as alternatives to fetal bovine serum in culture medium improves bovine embryo quality and trophoblast invasion by induction of matrix metalloproteinases. Reproduction, Fertility and Development, 2019, 31, 333.	0.1	29
468	CD73 complexes with emmprin to regulate MMP-2 production from co-cultured sarcoma cells and fibroblasts. BMC Cancer, 2019, 19, 912.	1.1	10
469	Oxalomalate suppresses metastatic melanoma through IDH-targeted stress response to ROS. Free Radical Research, 2019, 53, 418-429.	1.5	7
470	Biological barriers to cancer drug delivery, efficacy and cancer models. , 2019, , 359-423.		1
471	CXCL12/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K/AKT signal pathway. Journal of Cellular Biochemistry, 2019, 120, 9724-9736.	1.2	32
472	Pancreatic Stellate Cells Activation and Matrix Metallopeptidase 2 Expression Correlate With Lymph Node Metastasis in Pancreatic Carcinoma. American Journal of the Medical Sciences, 2019, 357, 16-22.	0.4	17
473	Identification of candidate aberrantly methylated and differentially expressed genes in Esophageal squamous cell carcinoma. Scientific Reports, 2020, 10, 9735.	1.6	11
474	The Pluripotent Activities of Caffeic Acid Phenethyl Ester. Molecules, 2021, 26, 1335.	1.7	39
475	Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options. Brain Tumor Pathology, 2021, 38, 156-172.	1.1	8
476	Influence of the Recombinant Heat Shock Protein 90Î² (HSP90Î²) on the Wound Healing Rate in Mice. Biology Bulletin, 2021, 48, 351-357.	0.1	0
477	Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. World Journal of Gastroenterology, 2021, 27, 2105-2121.	1.4	17

#	Article	IF	Citations
478	Evidence That Tumor Microenvironment Initiates Epithelial-To-Mesenchymal Transition and Calebin A can Suppress it in Colorectal Cancer Cells. Frontiers in Pharmacology, 2021, 12, 699842.	1.6	22
479	Expression of Matrix Metalloproteinase-9 in Gastric Cancer. Cureus, 2021, 13, e18195.	0.2	1
480	Piperine for treating breast cancer: A review of molecular mechanisms, combination with anticancer drugs, and nanosystems. Phytotherapy Research, 2022, 36, 147-163.	2.8	22
483	Interaction of Structured and Functionalized Polymers with Cancer Cells. , 0, , 233-250.		1
485	The Role of Matrix Metalloproteinases in an in Vitro Model of Bladder Tumor Invasion. Advances in Experimental Medicine and Biology, 1999, 462, 413-417.	0.8	2
486	Fibroblasts in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1234, 15-29.	0.8	59
487	Genetic instability and tumor cell variation. , 1998, , 179-234.		1
488	Tyrosyl Phosphorylated Serine-Threonine Kinase PAK1 is a Novel Regulator of Prolactin-Dependent Breast Cancer Cell Motility and Invasion. Advances in Experimental Medicine and Biology, 2015, 846, 97-137.	0.8	26
489	Zymography, Casein Zymography, and Reverse Zymography: Activity Assays for Proteases and their Inhibitors. , 1999, , 63-76.		9
490	The TSH Receptor. Handbook of Experimental Pharmacology, 1997, , 33-73.	0.9	10
491	Tympanic Membrane Metalloproteinase Inflammatory Response. Otolaryngology - Head and Neck Surgery, 2003, 129, 647-654.	1.1	1
492	Matrix metalloproteinaseâ€“1 is associated with poor prognosis in colorectal cancer. Nature Medicine, 1996, 2, 461-462.	15.2	240
493	The role of extracellular matrix in tumour angiogenesis: the throne has NOx servants. Biochemical Society Transactions, 2020, 48, 2539-2555.	1.6	8
494	Marimastat in Patients With Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 247-252.	0.6	101
495	Expression of Metalloproteinases and Tissue Inhibitor in Cartilaginous Neoplasms of Bone. Applied Immunohistochemistry & Molecular Morphology, 1997, 5, 111-116.	2.0	5
496	Highly expressed tumoral emmprin and stromal CD73 predict a poor prognosis for external auditory canal carcinoma. Cancer Science, 2020, 111, 3045-3056.	1.7	7
497	cDNA Sequence and mRNA Tissue Distribution of a Novel Human Matrix Metalloproteinase with a Potential Transmembrane Segment. FEBS Journal, 1995, 231, 602-608.	0.2	269
498	Retrovirus Targeting by Tropism Restriction to Melanoma Cells. Journal of Virology, 1999, 73, 6923-6929.	1.5	51

#	Article	IF	Citations
499	The Role of Plasminogen, Plasminogen Activators, and Matrix Metalloproteinases in Primate Arterial Smooth Muscle Cell Migration. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1373-1382.	1.1	75
500	Thrombin Promotes Activation of Matrix Metalloproteinase-2 Produced by Cultured Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 483-489.	1.1	109
501	Matrix Metalloproteinases and Cardiovascular Disease. Circulation Research, 1995, 77, 863-868.	2.0	709
502	Embryonic Endothelial Cells Transdifferentiate Into Mesenchymal Cells Expressing Smooth Muscle Actins In Vivo and In Vitro. Circulation Research, 1997, 80, 444-451.	2.0	287
503	Plasminogen Activator Inhibitor Type 1 and Tissue Inhibitor of Metalloproteinases-2 Increase After Arterial Injury in Rats. Circulation Research, 1997, 80, 490-496.	2.0	54
504	Cell Migration Induced by Native Type IV Collagen Requires PI3K/Akt2 and EGFR Activity in MDA-MB-231 Breast Cancer Cells. Cancer Research Journal, 2015, 3, 52.	0.0	1
505	Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.. Journal of Clinical Investigation, 1994, 94, 2493-2503.	3.9	2,209
506	Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-Î± and leaves RANTES and MCP-2 intact. Blood, 2000, 96, 2673-2681.	0.6	23
507	The Role of Type IV Collagenases in Rat Bladder Development and Obstruction. Pediatric Research, 1997, 41, 430-434.	1.1	19
508	MT-MMP, the cell surface activator of proMMP-2 (progelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. Journal of Cell Science, 1996, 109, 953-959.	1.2	140
509	Association between MMP1 -1607 1G>2G Polymorphism and Head and Neck Cancer Risk: A Meta-Analysis. PLoS ONE, 2013, 8, e56294.	1.1	11
510	Proteinases from pollen and pests.. Acta Biochimica Polonica, 1996, 43, 411-417.	0.3	2
511	Tetracyclines: Insights and Updates of their Use in Human and Animal Pathology and their Potential Toxicity. The Open Biochemistry Journal, 2019, 13, 1-12.	0.3	30
512	The expression of matrix metalloproteinase 9 and cathepsin B in gastric carcinoma is associated with lymph node metastasis, but not with postoperative survival.. Folia Histochemica Et Cytobiologica, 2008, 46, 57-64.	0.6	27
513	Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Disease Markers, 2010, 29, 37-46.	0.6	27
514	Ornithine decarboxylase, mitogen-activated protein kinase and matrix metalloproteinase-2 expressions in human colon tumors. World Journal of Gastroenterology, 2005, 11, 3065.	1.4	17
515	Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 5931.	1.4	59
516	Detection of gelatinase B activity in serum of gastric cancer patients. World Journal of Gastroenterology, 2006, 12, 105.	1.4	21

#	Article	IF	Citations
517	CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World Journal of Gastroenterology, 2012, 18, 1249.	1.4	58
518	Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World Journal of Gastroenterology, 2016, 22, 2678.	1.4	177
519	Immunohistochemical and clinical significance of matrix metalloproteinase-2 and its inhibitor in oral lichen planus. Journal of Oral and Maxillofacial Pathology, 2019, 23, 476.	0.3	6
520	Expression of High Mobility Group Box - B1 (HMGB-1) and Matrix Metalloproteinase-9 (MMP-9) in Non-small Cell Lung Cancer (NSCLC). Asian Pacific Journal of Cancer Prevention, 2014, 15, 4865-4869.	0.5	21
522	Molecular Pathogenesis of Cerebral Aneurysms: Current Concepts and Future Directions. , 2003, , 26-41.		0
523	Angiotensin II and Vascular Extracellular Matrix. Handbook of Experimental Pharmacology, 2004, , 39-63.	0.9	1
524	Extracellular Matrix and Organ Transplantation. , 2004, , 575-589.		0
525	Urokinasetyp-Plasminogenaktivator (uPA), sein Inhibitor PAI-1 und sein Rezeptor (CD87) sind an Tumorinvasion und Metastasierung solider maligner Tumoren beteiligt. , 1996, , 167-188.		0
526	The concertration of matrix metallproteinase in head and neck carcinomas.. Japanese Jornal of Head and Neck Cancer, 1997, 23, 150-155.	0.1	0
528	Angiogenesis and Metastasis. , 1997, , 40-53.		0
529	Purification and Characterization of Matrix Metalloproteinase-3 (Stromelysin-1) from Bovine Interphotoreceptor Matrix. , 1997, , 399-407.		0
531	Cell-associated metalloproteinases. , 1999, , 73-93.		3
532	Oral Antibiotics as Anti-inflammatories. , 2015, , 237-251.		0
533	Characterization of autofluorescence in normal and necrosed muscles in chickens. Journal of Veterinary Medical Research, 2017, 24, 205-210.	0.2	0
534	Circulating gelatinases are not prognostic of treatment response and survival in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy. Journal of Cancer Research and Therapeutics, 2018, 14, 90.	0.3	0
536	Membrane-Type Matrix Metalloproteinases. , 2002, , 109-125.		0
538	Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO Journal, 1995, 14, 908-17.	3.5	52
539	Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. American Journal of Pathology, 1996, 148, 611-22.	1.9	76

#	Article	IF	Citations
540	Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas. American Journal of Pathology, 1996, 148, 539-48.	1.9	25
541	Distribution of integrin cell adhesion molecules in endometrial cancer. American Journal of Pathology, 1995, 146, 717-26.	1.9	47
542	Association between matrix metalloproteinase 1 -1607 1G>2G polymorphism and cancer risk: a meta-analysis including 19706 subjects. International Journal of Clinical and Experimental Medicine, 2014, 7, 2992-9.	1.3	5
543	Extracellular Matrix Remodeling by Fibroblast-MMP14 Regulates Melanoma Growth. International Journal of Molecular Sciences, 2021, 22, 12276.	1.8	13
544	14-3-3 Sigma Protein Contributes to Hepatocyte Growth Factor-mediated Cell Proliferation and Invasion via Matrix Metalloproteinase-1 Regulation in Human Gastric Cancer. Anticancer Research, 2022, 42, 519-530.	0.5	3
545	Metastatic Tumours. , 0, , 1464-1478.		0
547	Matrix Metalloproteinases in a Gerbil Cholesteatoma Model. Otolaryngology - Head and Neck Surgery, 2003, 129, 402-407.	1.1	1
550	The Extracellular Matrix: Its Composition, Function, Remodeling, and Role in Tumorigenesis. Biomimetics, 2023, 8, 146.	1.5	8